JD Supra17d
FDA Approved Journavx, a Non-Opioid Drug for Pain Management
Because of the recent approval by the FDA, it is anticipated payers will see an up-tick in the number of requests for this new drug. Because Journavx is not listed on the formulary, all requests ...
BioPharma Dive3d
Tris to ask for approval of dual-acting pain drug
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
3 Magnificent Growth Stocks to Buy in March
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
AFP12d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...
Nasdaq24d
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment for moderate to severe acute pain. For the healthcare industry, this can be a valuable ...
WRIC14d
FDA approves first opioid-free painkiller in over two decades
RICHMOND, Va. (WRIC) — The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.
RBC says Journavx review documents hint at focus in future chronic pain data
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.